Maintenance Therapy and Adherence to COPD Treatment

Author(s):

M. Bradley Drummond, MD, MHS,MeiLan K. Han, MD, MS

Panelists discuss how individualized chronic obstructive pulmonary disease (COPD) maintenance therapy considers symptom severity, exacerbation risk, and eosinophil levels. Dupilumab and ensifentrine require adherence to prescribed dosing for efficacy and safety.

EP: 1.Overview and Diagnosis of COPD

EP: 2.Risk Factors for COPD

EP: 3.Mortality and Comorbidities with COPD

EP: 4.Health and Economic Burden of COPD

EP: 5.Treatment of COPD Based on Symptoms

EP: 6.GOLD 2025 Report: Prebronchodilator Spirometry and Diagnosis of COPD

EP: 7.GOLD 2025 Report: Lung Microbiome and Chest CT Imaging in COPD

EP: 8.GOLD 2025 Report: Addressing Heart Disease in COPD

EP: 9.Blood Eosinophil Counts in COPD

EP: 10.GOLD 2025 Report: Ensifentrine, a New Treatment in COPD

EP: 11.GOLD 2025 Report: Dupilumab, a New Treatment in COPD

EP: 12.Ensifentrine (ENHANCE Trials) in COPD

Now Viewing

EP: 13.Maintenance Therapy and Adherence to COPD Treatment

Video content above is prompted by the following:

What are key considerations when selecting individualized maintenance therapy for COPD?
What are the dosing and administration recommendations for dupilumab and ensifentrine? Is treatment adherence a concern with either agent?